Compare MNTK & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MNTK | NNNN |
|---|---|---|
| Founded | 1980 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 267.6M | 270.4M |
| IPO Year | 2020 | 2023 |
| Metric | MNTK | NNNN |
|---|---|---|
| Price | $2.40 | $4.49 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $1.70 | N/A |
| AVG Volume (30 Days) | ★ 860.9K | 151.2K |
| Earning Date | 11-04-2026 | 10-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | N/A |
| Revenue | ★ $176,382,000.00 | N/A |
| Revenue This Year | $20.76 | N/A |
| Revenue Next Year | $16.15 | N/A |
| P/E Ratio | ★ $146.00 | $446.57 |
| Revenue Growth | ★ 0.37 | N/A |
| 52 Week Low | $1.07 | $4.16 |
| 52 Week High | $3.28 | $44.73 |
| Indicator | MNTK | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 47.35 | 29.31 |
| Support Level | $1.40 | N/A |
| Resistance Level | $2.73 | $6.95 |
| Average True Range (ATR) | 0.27 | 0.57 |
| MACD | -0.05 | -0.03 |
| Stochastic Oscillator | 15.69 | 10.55 |
Montauk Renewables Inc is a renewable energy company. It specializes in the recovery and processing of biogas from landfills and other non-fossil fuel sources for beneficial use as a replacement for fossil fuels. The firm develops, owns, and operates RNG projects that supply renewable fuel into the transportation and electrical power sectors. Montauk operates in two segments namely Renewable Natural Gas and Renewable Electricity Generation. It generates a majority of its revenue from the Renewable Natural Gas segment.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).